To confirm the existence of our newly described AREG+ cDC2 subpopulation, we performed flow cytometry on blood and CSF obtained from 4 MS subjects (Supplemental Table 4) using a collection of informative surface markers (Supplemental Figure 4, A and B). Here, AREG is linked to myeloid sarcoma.